Labrie F, Dupont A, Belanger A, Lachance R, Giguere M
Br Med J (Clin Res Ed). 1985 Aug 10;291(6492):369-70. doi: 10.1136/bmj.291.6492.369.
Serum concentrations of luteinising hormone and testosterone were measured by radioimmunoassay one, two, four, seven, and 24 hours after the subcutaneous administration of 500 micrograms of the luteinising hormone releasing hormone agonist [D-Trp6, des-Gly-NH2(10)] LHRH ethylamide or [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide in patients who had previously received daily treatment with these peptides for 0, 1, 6, 12, 18, and 24 months. No increase in the serum concentrations of luteinising hormone or testosterone were detected at any time between one and 24 months' treatment. The data show that daily subcutaneous administration of the two luteinising hormone releasing hormone agonists used at the appropriate dose can maintain concentrations of serum androgens equivalent to those after castration during long term treatment.
在曾接受每日一次这些肽类药物治疗0、1、6、12、18和24个月的患者中，皮下注射500微克促黄体生成素释放激素激动剂[D-色氨酸6，去甘氨酰胺（10）]促黄体生成素释放激素乙酰胺或[D-丝氨酸（叔丁基）6，去甘氨酰胺（10）]促黄体生成素释放激素乙酰胺后1、2、4、7和24小时，通过放射免疫分析法测定血清促黄体生成素和睾酮浓度。在治疗1至24个月期间的任何时间，均未检测到血清促黄体生成素或睾酮浓度升高。数据表明，长期治疗期间，每日皮下注射适当剂量的两种促黄体生成素释放激素激动剂可维持血清雄激素浓度，使其与去势后相当。
